A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

Clinical trial NCT07160335 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07160335
Sponsor: Shanghai Henlius Biotech
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Melanoma Renal Cell Carcinoma

Start date: 2025-09-26
Primary completion: 2027-04-30
Enrollment: 174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.